Q3 2023 · 13F-HR
Omega Fund Management, LLCholdings as filed
Filed 2023-11-14 · accession 0000950123-23-010476
$108.9M
Reported value
12
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76029N106 | REPL | Replimune Group | $51.4M | 47.2% | 3,001,319 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio | $20.2M | 18.6% | 15,072,340 | Common | SOLE |
| 45175G108 | — | Ikena Oncology | $9.7M | 8.94% | 2,249,123 | Common | SOLE |
| 61775R105 | MORFUSD | Morphic Holding | $7.1M | 6.52% | 309,846 | Common | SOLE |
| 50107A104 | KRON1USD | Kronos Bio | $5.0M | 4.56% | 3,818,283 | Common | SOLE |
| 85209E109 | — | Spruce Biosciences | $4.9M | 4.49% | 2,161,022 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $3.3M | 3.00% | 843,750 | Common | SOLE |
| 4525EP101 | VTLUSD | Immunic Inc | $2.6M | 2.41% | 1,788,160 | Common | SOLE |
| 88369M101 | — | Theseus Pharmaceuticals | $1.9M | 1.76% | 711,479 | Common | SOLE |
| 02083G100 | NVLSEUR | Alpine Immune Sciences | $1.8M | 1.62% | 153,700 | Common | SOLE |
| 87184Q206 | SYRS | Syros Pharmaceuticals | $992,517 | 0.91% | 251,270 | Common | SOLE |
| 81726A100 | — | Senti Biosciences, Inc. | $80,862 | 0.07% | 195,792 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.